DUBLIN--(BUSINESS WIRE)--The "Microneedles and Needle-Free Injection Systems / Jet Injectors (Devices based on Spring, Gas and Other Mechanisms) Market, 2019-2030" report has been added to ResearchAndMarkets.com's offering.
The field of needleless drug delivery continues to witness significant advances, in terms of innovation in drug/therapy administration (such as dose tracking and real-time updates) and the development of compatible drug formulations. As a result, several stakeholders in the healthcare industry have developed interest in this upcoming field, and have launched product development/commercialization initiatives in the recent past.
This report features an extensive study of the current landscape and the likely future opportunities associated with the needle-free injection systems and microneedles market, over the next 10-12 years. Amongst other elements, the report includes:
- A detailed review of the overall landscape of the needle-free injection systems market, featuring a comprehensive list of device developers and analysis based on a number of parameters, such as year of establishment, company size, geographical location, current development status of various products (under development and commercialized), details on intellectual property portfolio, route of administration (subcutaneous, intramuscular, intradermal and others), type of load (solid and liquid), usability (disposable and reusable), actuation mechanism (spring-based, gas-powered and others), capacity of the device (in terms of volume of drug delivered) and target disease areas.
- An overview of the current market landscape of microneedle devices, featuring a comprehensive list of device developers and analysis based on a number of parameters, such as year of establishment, company size, geographical location, current development status of various products (under development and commercialized), details on intellectual property portfolio, type of microneedle device (hollow, solid and dissolving), route of administration (subcutaneous, transdermal, intradermal and others), microneedle length and target disease areas.
- A detailed product competitiveness analysis of both needle-free injection systems and microneedle devices, taking into consideration the supplier power (based on the year of establishment of developer company) and key product specifications. For needle-free injection systems, specifications, such as therapeutic area, route of administration, maximum device volume, usability, size of intellectual property portfolio, and commercial availability, were considered. For microneedles, specifications, such as therapeutic area, route of administration, length of microneedle, and size of intellectual property portfolio, were considered.
- A list of marketed drugs/therapies and pipeline candidates that are anticipated to be developed in combination with needle free injectors and microneedles in the near future; the analysis is based on a variety of relevant parameters, such as (in alphabetical order) current status of development, dose concentration, dosing frequency, route of administration, type of dose (standard/weight dependent), expected patent expiry (relevant only for marketed drugs) and information on product sales (relevant only for marketed drugs).
- An informed business portfolio analysis based on an attractiveness and competitiveness (AC) framework, highlighting the current worth of different types of needle-free injection systems and microneedle devices.
- Elaborate profiles of prominent product developers engaged in this domain. Each profile features a brief overview of the company, its financial information (if available), information on its product portfolio and recent developments.
- A case study on the role of contract manufacturing organizations within the medical device industry. It includes a brief description of the various regulatory guidelines for medical devices and highlights the challenges associated with the manufacturing of such products. In addition, it features a list of contract manufacturers that claim to offer services for drug delivery devices and their geographical landscape.
One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for needle-free injection systems and microneedle devices. Based on various parameters, such as number of marketed/pipeline products, existing price of devices (for commercially available products only) and estimated annual adoption rate, we have provided an informed estimate on the likely evolution of the market over the period 2019-2030.
For needle-free injection systems, the report also features the likely distribution of the current and forecasted opportunity across [A] different types of actuation mechanisms (spring-based, gas powered and others), [B] routes of administration (subcutaneous, intramuscular and intradermal), [C] target disease indication (infectious diseases, diabetes, pain disorders and others), [D] product usability (disposable and re-usable) and [E] key geographical regions (North America, Europe, Asia and Rest of the World).
Similarly, the projected future opportunity for microneedle devices has been analyzed across [A] various types of microneedle devices (hollow, solid and dissolving), [B] target disease indication (infectious diseases, osteoarthritis, pain disorders, cancer, and others), [C] type of intervention (vaccines, therapeutic agent and others), and [D] key geographical regions (North America, Europe, Asia and Rest of the World).
In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.
The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:
- Michael Schrader, CEO and Founder, Vaxess Technologies
- Patrick Anquetil, CEO, Portal Instruments
- Henry King, Market Intelligence and Business Development Manager, Innoture
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Key Topics Covered
1 PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2 EXECUTIVE SUMMARY
3 INTRODUCTION
3.1 Chapter Overview
3.2. Conventional Parenteral Drug Delivery
3.2.1. Needlestick Injuries
3.2.2. Incidence and Cost Burden Related to Needlestick Injuries
3.3. Minimally Invasive Drug Delivery
3.3.1. Key Drivers of Minimally Invasive Drug Delivery Systems
3.3.1.1. Rising Burden of Chronic Diseases
3.3.1.2. Healthcare Cost Savings
3.3.1.3. Need for Immediate Treatment in Emergency Situations
3.3.1.4. Growing Injectable Drugs Market
3.3.1.5. Need for Improving Medication Adherence
3.4. Needle-Free Injection Technology
3.5. Drug Delivery through Microneedle Devices
3.6. Needle-Free Injection Systems and Microneedle Devices: Unaddressed Challenges
3.7. Future of Needle-Free Injection Systems and Microneedle Devices
4 NEEDLE-FREE INJECTION SYSTEMS: MARKET OVERVIEW
4.1. Chapter Overview
4.2. Needle-Free Injection Systems: List of Developers
4.3. Needle-Free Injection Systems: List of Available / Under Development Devices
4.4. Needle-Free Injection Systems: Additional Information
4.5. Needle-Free Injection Systems: Recent Partnerships (2015-2019)
5 MICRONEEDLE DEVICES: MARKET OVERVIEW
5.1. Chapter Overview
5.2. Microneedle Devices: List of Developers
5.3. Microneedle Devices: List of Available / Under Development Devices
6 PRODUCT COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Assumptions and Key Parameters
6.4. Product Competitiveness Analysis: Needle-Free Injection Systems
6.5. Product Competitiveness Analysis: Microneedle Devices
7 COMPANY PROFILES
7.1. Chapter Overview
7.2. Inovio Pharmaceuticals
7.3. Medical International Technology
7.4. D'Antonio Consultants International
7.5. Enesi Pharma
7.6. PharmaJet
7.7. Inolife Sciences
7.8. Valeritas
7.9. NanoPass Technologies
7.10. 3M
7.11. Micropoint Technologies
7.12. Nemaura Pharma
8 AC MATRIX
8.1. Chapter Overview
8.2. AC Matrix: An Overview
8.3. AC Matrix: Analytical Methodology
8.4. AC Matrix: Plotting the Information
8.5. AC Matrix: Analyzing the Data
8.6. Concluding Remarks
9 CASE STUDY: DRUG DELIVERY DEVICE CONTRACT MANUFACTURERS
9.1. Chapter Overview
9.2. Challenges Associated with Medical Device Manufacturing
9.3. Role of Contract Manufacturing Organizations in the Device Development Process
9.4. Regulatory Guidelines for Medical Devices
9.5. Drug Delivery Device: List of Contract Manufacturers
9.6. Geographical Distribution of Device Developers and Contract Service Providers
10 NEEDLE-FREE INJECTION SYSTEMS: LIKELY DRUG CANDIDATES
10.1. Chapter Overview
10.2. Marketed Drugs Candidates
10.3. Clinical Drug Candidates (Biologics)
10.4. Clinical Drug Candidates (Small Molecules)
11 MICRONEEDLE DEVICES: LIKELY DRUG CANDIDATES
11.1. Chapter Overview
11.2. Marketed Drugs Candidates
11. 2.3. Less Likely Candidates for Delivery via Microneedle Devices
11. 2.4. Unlikely Candidates for Delivery via Microneedle Devices
11.3. Clinical Drug Candidates (Biologics)
11. 3.2. Likely Candidates for Delivery via Microneedle Devices
11. 3.3. Less Likely Candidates for Delivery via Microneedle Devices
11. 3.4. Unlikely Candidates for Delivery via Microneedle Devices
11.4. Clinical Drug Candidates (Small Molecules)
12 MARKET SIZING AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Needle-Free Injection Systems Market, 2019-2030
12.4. Global Needle-Free Injection Systems Market: Distribution by Actuation Mechanism, 2019-2030
12.5. Global Needle-Free Injection Systems Market: Distribution by Route of Administration, 2019-2030
12.6. Global Needle-Free Injection Systems Market: Distribution by Target Disease Indication, 2019-2030
12.7. Global Needle-Free Injection Systems Market: Distribution by Product Usability, 2019-2030
12.8. Global Needle-Free Injection Systems Market: Distribution by Regions, 2019-2030
12.9. Global Microneedle Devices Market, 2019-2030
12.10. Global Microneedle Devices Market: Distribution by Type of Microneedle, 2019-2030
12.11. Global Microneedle Devices Market: Distribution by Target Disease Indication, 2019- 2030
12.12. Global Microneedle Devices Market: Distribution by Type of Intervention, 2019-2030
12.13. Global Microneedle Devices Market: Distribution by Regions, 2019-2030
13 INTERVIEW TRANSCRIPTS
13.1. Chapter Overview
13.2. Vaxess Technologies
13.3. Portal Instruments
13.3. Innoture
14 CONCLUDING REMARKS
15 APPENDIX 1: TABULATED DATA
16 APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Companies Mentioned
- 3M
- AbbVie
- AbGenomics
- Ablynx
- ABO Pharmaceuticals
- Acceleron Pharma
- Actavis Pharma
- Activa Brand Products
- ADC Therapeutics
- AdminMed
- Adrenomed
- Aduro Biotech
- Advaxis
- Aeglea BioTherapeutics
- Affibody
- Agenus
- AgonOx
- Aijex Pharma International
- AIM ImmunoTech
- Akesobio Australia
- AKRA DERMOJET
- Alder BioPharmaceuticals
- Alector
- Alexion Pharmaceuticals
- Alkahest
- Alkermes
- Allakos
- Allergan
- Allozyne
- Alnylam Pharmaceuticals
- AlphaCore Pharma
- Altor BioScience
- Ambrx
- amcure
- American Medical Systems
- AMETEK Engineered Medical Components
- Amgen
- Amicus Therapeutics
- Amphivena Therapeutics
- Amplyx Pharmaceuticals
- Amsino
- Anesiva
- Angiochem
- Antares Pharma
- Antaros Medical
- Apex Medical Technologies
- Apogee Technology
- Aprea Therapeutics
- Aptevo Therapeutics
- argenx
- and many, many more...
For more information about this report visit https://www.researchandmarkets.com/r/64f1qs
